Post-traumatic Headache Not Relieved by Acute IV Therapy: What Comes Next?
When a full course of acute intravenous treatment for post-traumatic headache has not achieved adequate pain relief, the clinical situation calls for a structured next-line approach — one focused on prevention rather than further acute intervention.
Previous Treatment — Goal Not Reached
The prior step involved acute IV therapies for refractory headache: intravenous ketorolac combined with an IV dopamine receptor antagonist (metoclopramide or prochlorperazine) and intravenous fluids, with alternatives including a greater occipital nerve block or an oral corticosteroid bridge. The target — relief or reduction of acute headache — was not achieved, indicating the need to move to the next line.
Next-Line Approach
This protocol introduces a preventive nutraceutical strategy started in the early post-injury period. It involves specific supplements with well-established safety profiles, with a structured reassessment point built in at two weeks. The complete regimen — which agents, in what sequence, and what to do if headache persists beyond the initial window — is set out in the full structured protocol.
Treatment Goal
Reduction or resolution of headache, reassessed at two weeks and across a defined preventive trial period.
References
DOI: 10.1111/head.14795
- Short courses of riboflavin and magnesium can be considered immediately after injury, as they have shown benefit within 48 h of concussion and have favorable side-effect profiles.
- For adolescents and young adults at high risk of PPTH, considerations include riboflavin and magnesium.
- If significant headache persists after 2 weeks, riboflavin 400 mg daily and magnesium 400–500 mg nightly for headache prevention can be trialed giving 6–8 weeks to see benefit, consistent with migraine recommendations.
- Melatonin 3–5 mg nightly for an 8-week course may be considered for youth with comorbid sleep disruption.
View source ↗